UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.36M | -33.35M | -49.94M | -43.84M | -37.51M |
| Total Depreciation and Amortization | 679.00K | 639.00K | 596.00K | 497.00K | 306.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.42M | 5.29M | 3.67M | 3.17M | 8.06M |
| Change in Net Operating Assets | -17.06M | -14.85M | 5.85M | -1.85M | 15.53M |
| Cash from Operations | -38.33M | -42.27M | -39.83M | -42.02M | -13.62M |
| Capital Expenditure | -17.00K | -87.00K | -141.00K | -44.00K | -115.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.73M | 31.49M | 28.55M | -25.92M | 60.74M |
| Cash from Investing | 27.72M | 31.40M | 28.41M | -25.96M | 60.62M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -1.86M | -- | -- | -- | -- |
| Issuance of Common Stock | 33.17M | 8.27M | 293.00K | 34.00K | 71.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.00K | 0.00 | 3.00K | -- | 0.00 |
| Cash from Financing | 31.32M | 8.27M | 296.00K | 34.00K | 71.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.71M | -2.60M | -11.12M | -67.95M | 47.07M |